Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

2021120 citationsJournal Articlebronze Open Access

Authors

Hiddo J.L. Heerspink · University Medical Center Groningen

C. David Sjöström · AstraZeneca (Sweden)

Niels Jongs · University Medical Center Groningen

Glenn M. Chertow · Stanford University

Mikhail Kosiborod · The George Institute for Global Health

Fan Fan Hou · Nanfang Hospital

John J.V. McMurray

Abstract

In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Chronic Kidney Disease and Diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal

Volume 42, Issue 13, pp. 1216-1227

DOI: 10.1093/eurheartj/ehab094

Field-Weighted Citation Impact: 14.82